Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Subscribe To Our Newsletter
THE AMFM ENDANGERS PUBLIC HEALTH, OXFAM SAYS
GFO Issue 200

THE AMFM ENDANGERS PUBLIC HEALTH, OXFAM SAYS

Author:

Frank Wafula and David Garmaise

Article Type:
News

Article Number: 1

Global Fund calls Oxfam’s claims “untrue”

ABSTRACT A report from Oxfam is very critical of the Affordable Medicine Facility–malaria, which is hosted by the Global Fund.

The Affordable Medicine Facility–malaria (AMFm) endangers public health, according to Oxfam. There are alternative approaches that can deliver better health outcomes for poor people, the agency said in a report released on 24 October 2012.

The AMFm is a subsidy programme for artemisinin-based combination therapies (ACTs) currently underway in seven pilot countries. A recently concluded independent evaluation termed the AMFm a “game-changer,” having successfully increased the availability and reduced the prices for quality ACTs among the private sector providers (see GFO article).

The Global Fund has hosted the AMFm as a pilot project since 2009. The Board of the Global Fund is scheduled to decide on the future of the AMFm at its meeting on 14–15 November.

According to the Oxfam report, increased availability is not proof that the medicines got to those in need or that treatments were given appropriately. The report blamed AMFm for causing “a crisis in the global market” by triggering excessive demand for ACTs, even among countries with low malaria prevalence.

The report warned of the danger of resistance as a result of excessive sale of ACTs, particularly now when malaria cases are known to be on the decline.

Oxfam also faulted the AMFm model’s reliance on the private retail sector. The report argued that such providers lack the incentive to carry out proper diagnosis and treatment. Instead, Oxfam recommended that community health workers be trained on diagnosis and treatment, and that private pharmacies only support public sector provision in towns.

Oxfam also recommended that the Global Fund stop hosting the AMFm and that UNITAID and the UK Department for International Development, two of the main donors, cease funding the project.

According to BBC News, the Global Fund issued a statement in response to the Oxfam report in which it said Oxfam’s claims were “simply untrue.”

The Fund said, “Some Western aid groups oppose a pragmatic approach that includes any involvement of the private sector. But the reality of this programme is that it is getting life-saving medicine to people who need it most from the private sector outlets where they already seek treatment.”

Leave a reply

  • Anonymous comments (0)
  • Facebook Comments

Your email address will not be published.

Aidspan

Categories*

Loading
Aidspan

Categories*

Loading